Search Result

Results for "

triple negative breast cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Akt (3) Anaplastic lymphoma kinase (ALK) (1) Annexin A (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (49) Aryl Hydrocarbon Receptor (1) Aurora Kinase (3) Autophagy (13) Bcl-2 Family (6) Biochemical Assay Reagents (1) Casein Kinase (2) Caspase (2) CD73 (1) CDK (8) ClpP (1) CXCR (1) DNA Methyltransferase (1) DNA/RNA Synthesis (3) DYRK (1) EGFR (2) Endogenous Metabolite (3) Epigenetic Reader Domain (4) ERK (2) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (6) FGFR (1) Fluorescent Dye (1) Fungal (1) GLUT (1) Glutaminase (2) Glutathione Peroxidase (2) HDAC (8) Histone Methyltransferase (5) HIV (1) IAP (1) IGF-1R (1) Influenza Virus (1) Interleukin Related (1) JAK (1) Ligands for E3 Ligase (1) MDM-2/p53 (5) MicroRNA (2) MNK (1) mTOR (3) NF-κB (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PAI-1 (1) PAK (1) PARP (4) PD-1/PD-L1 (1) PERK (1) Phosphatase (4) PI3K (2) PPAR (1) PROTACs (5) Protein Arginine Deiminase (2) PSMA (1) Pyruvate Kinase (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) RAR/RXR (1) Ras (3) Reactive Oxygen Species (3) Ribosomal S6 Kinase (RSK) (1) ROCK (1) SARS-CoV (1) Ser/Thr Protease (1) SHP2 (1) Sirtuin (2) Src (1) STAT (5) Survivin (1) Transmembrane Glycoprotein (1) TROP2 (3) ULK (4) VD/VDR (1) VEGFR (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (125) Infection (3) Inflammation/Immunology (5)
Click Chemistry:	Alkynes (4)

124

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: BCRP BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101923B

LYN-1604 dihydrochloride 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923

LYN-1604 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-131339

SP-96 1 Publications Verification	Aurora Kinase	Cancer
SP-96 is a?highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-114979

Pyoluteorin	Antibiotic Fungal Apoptosis	Infection Cancer
Pyoluteorin is an antibiotic that inhibits Oomycete fungi, including the plant pathogen Pythium ultimum, and suppresses plant diseases caused by this fungus . Pyoluteorin induces human triple-negative breast cancer MDA-MB-231 cells apoptosis in vitro. Pyoluteorin can be used for the research of human triple-negative breast cancer .

HY-161831

Antitumor agent-175	Reactive Oxygen Species	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

HY-170786

IRX5010 IRX4647F	RAR/RXR	Cancer
IRX5010 (IRX4647F), an analogue of IRX4647, is a highly selective RARγ nuclear receptor agonist. IRX5010 demonstrates inhibition of in vivo growth of EMT-6 triple negative breast cancer .

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-147373

DA-PROTAC	PROTACs Ligands for E3 Ligase	Cancer
DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research .

HY-12015

Iniparib 5+ Cited Publications BSI-201; NSC-746045; IND-71677	PARP Influenza Virus	Cancer
Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

HY-142908

Maximiscin	Endogenous Metabolite	Cancer
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-132883

EGFR/CSC-IN-1	EGFR	Cancer
EGFR/CSC-IN-1 is a potential EGFR (IC₅₀ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer research.

HY-139742

ADTL-SA1215	Sirtuin	Cancer
ADTL-SA1215 is a first-in-class specific small-molecule activator of SIRT3 that modulates autophagy in triple negative breast cancer.

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .

HY-150757

Autophagy-IN-2	Autophagy Apoptosis	Cancer
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research .

HY-163381

Antiproliferative agent-48	Others	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

HY-152536

iNOS inhibitor-10	NO Synthase	Cancer
iNOS inhibitor-10 is an iNOS inhibitor (IC₅₀: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells .

HY-N0770

Isoliensinine	Apoptosis	Inflammation/Immunology Cancer
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC) .

HY-19634

YK-3-237	Sirtuin	Cancer
YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .

HY-149847

JH530	Ras	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-148761

PSMA I&T	PSMA	Cancer
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .

HY-148368

CYD-4-61	Bcl-2 Family Apoptosis	Cancer
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis .

HY-148923

MC0704	STAT	Cancer
MC0704 is a STAT3 inhibitor with an IC₅₀ value of 2.13 μM. MC0704 induces cell apoptosis and cell cycle arrest. MC0704 shows antitumor activity in mouse breast cancer models. MC0704 can be used for the research of metastatic triple-negative breast cancer (mTNBC) .

HY-N7215

Jatrophone	β-catenin Wnt	Cancer
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-132885

PARP/EZH2-IN-1	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and EZH2 (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-168951

(R)-SL18	Annexin A Apoptosis	Cancer
(R)-SL18 is a degrader of ANXA3 and can degrade ANXA3 protein through the ubiquitination pathway. (R)-SL18 inhibits the proliferation, migration, invasion, and colony formation of breast cancer cells and induces apoptosis. (R)-SL18 can be used in the research of triple-negative breast cancer .

HY-122703

BETi-211	Epigenetic Reader Domain	Cancer
BETi-211 is an orally active BET inhibitor (K_i: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC₅₀ < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors .

HY-155251

anti-TNBC agent-3	Apoptosis Bcl-2 Family	Cancer
anti-TNBC agent-3 (compound 3g) is an apoptosis inducer with anti-cancer cell proliferation activity. anti-TNBC agent-3 inhibits tumor growth and metastasis in triple-negative breast cancer (TNBC) xenograft models .

HY-173042

CDK12/13-IN-2	CDK	Cancer
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12/13, with IC₅₀ values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. CDK12/13-IN-2 can inhibit the proliferation of breast cancer cells and can be used in the research of triple-negative breast cancer .

HY-170972

PARP/NAMPT-IN-1	Apoptosis	Cancer
PARP/NAMPT-IN-1 (Compound 13j) is a dual PARP/NAMPT inhibitor with IC₅₀ values of 0.8 nM and 18 nM for PARP1 and NAMPT, respectively. PARP/NAMPT-IN-1 can inhibit the proliferation, migration and induce apoptosis of breast cancer cells. PARP/NAMPT-IN-1 can be used for the research of triple-negative breast cancer .

HY-139950

Rasarfin 1 Publications Verification	Ras	Cancer
Rasarfin is a dual Ras and ARF6 inhibitor .

HY-124909A

FR054	Phosphatase	Cancer
FR054 is an inhibitor of the HBP enzyme PGM3, with a remarkable anti-breast cancer effect .

HY-155490

Nur77 antagonist 1	Nuclear Hormone Receptor 4A/NR4A Apoptosis	Cancer
Nur77 antagonist 1(Compound ja) is a selective Nur77 antagonist(K_D ^SPR_Nur77 = 91 nM). Nur77 antagonist 1 induces cancer cell apoptosis. ja displays excellent antitumor against triple-negative breast cancer (TNBC) cells .

HY-101567

BMS-986158 2 Publications Verification	Epigenetic Reader Domain	Cancer
BMS-986158 is a potent BET inhibitor with IC₅₀s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits MDM2-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-168950

ANXA3 degrader 1	Annexin A	Cancer
ANXA3 degrader 1 (Compound 18a5) is a highly selective ANXA3 degrader with cancer cell inhibition activity. ANXA3 degrader 1 displays excellent inhibitory effect in a triple-negative breast cancer (TNBC) tumor xenograft model (TGI = 96%) .

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	STAT	Cancer
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-N6007

Chrysosplenol D	Apoptosis	Infection Inflammation/Immunology Cancer
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities .

HY-169130

Lyso BD-1	Fluorescent Dye	Cancer
Lyso BD-1, preferentially colocalized in lysosomes and lipid droplets, displays excellent photocytotoxicity (5.57 μM) on triple negative breast cancer cells under white light. Lyso BD-1 displays emission band at 560nm .

HY-161601

Ferroptosis inducer-2	Ferroptosis Reactive Oxygen Species	Cancer
Ferroptosis inducer-2 (Compound 24) is an inducer for heme oxygenase-1 (HO-1). Ferroptosis inducer-2 exhibits anticancer activity against triple-negative breast cancer (TNBC) cells through induction of ferroptosis .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-172139

PI3Kα-IN-25	PI3K	Cancer
PI3Kα-IN-25 (Compound Djh1) is a selective PI3Kα inhibitor. PI3Kα-IN-25 can be used in triple-negative breast cancer research .

HY-156816

ON 108600	Casein Kinase DYRK	Cancer
ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC₅₀s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

2,350 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,350 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-169130

Lyso BD-1	Fluorescent Dyes/Probes
Lyso BD-1, preferentially colocalized in lysosomes and lipid droplets, displays excellent photocytotoxicity (5.57 μM) on triple negative breast cancer cells under white light. Lyso BD-1 displays emission band at 560nm .

Cat. No.	Product Name	Target	Research Area

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Cat. No.	Product Name	Target	Research Area

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .

Cat. No.	Product Name		Classification

HY-135699

TD52 1 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 1 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

HY-132913

Cyclopropenone probe 1		Alkynes
Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Cyclopropenone probe 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks